162 related articles for article (PubMed ID: 35075163)
21. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
[TBL] [Abstract][Full Text] [Related]
22. Integrating multi-omics biomarkers and postprandial metabolism to develop personalized treatment for anorexia nervosa.
Shih PB
Prostaglandins Other Lipid Mediat; 2017 Sep; 132():69-76. PubMed ID: 28232135
[TBL] [Abstract][Full Text] [Related]
23. Proteomic profiling of pancreatic cancer for biomarker discovery.
Chen R; Pan S; Brentnall TA; Aebersold R
Mol Cell Proteomics; 2005 Apr; 4(4):523-33. PubMed ID: 15684406
[TBL] [Abstract][Full Text] [Related]
24. High-throughput and high-sensitivity quantitative analysis of serum unsaturated fatty acids by chip-based nanoelectrospray ionization-Fourier transform ion cyclotron resonance mass spectrometry: early stage diagnostic biomarkers of pancreatic cancer.
Zhang Y; Qiu L; Wang Y; Qin X; Li Z
Analyst; 2014 Apr; 139(7):1697-706. PubMed ID: 24551873
[TBL] [Abstract][Full Text] [Related]
25. The application of mass spectrometry to proteomics and metabolomics in biomarker discovery and drug development.
Mikami T; Aoki M; Kimura T
Curr Mol Pharmacol; 2012 Jun; 5(2):301-16. PubMed ID: 22122469
[TBL] [Abstract][Full Text] [Related]
26. Metabolomics identifies serum and exosomes metabolite markers of pancreatic cancer.
Tao L; Zhou J; Yuan C; Zhang L; Li D; Si D; Xiu D; Zhong L
Metabolomics; 2019 May; 15(6):86. PubMed ID: 31147790
[TBL] [Abstract][Full Text] [Related]
27. Towards proteome standards: the use of absolute quantitation in high-throughput biomarker discovery.
Chao TC; Hansmeier N; Halden RU
J Proteomics; 2010 Jun; 73(8):1641-6. PubMed ID: 20399287
[TBL] [Abstract][Full Text] [Related]
28. INDEED: Integrated differential expression and differential network analysis of omic data for biomarker discovery.
Zuo Y; Cui Y; Di Poto C; Varghese RS; Yu G; Li R; Ressom HW
Methods; 2016 Dec; 111():12-20. PubMed ID: 27592383
[TBL] [Abstract][Full Text] [Related]
29. Identification of Analytical Factors Affecting Complex Proteomics Profiles Acquired in a Factorial Design Study with Analysis of Variance: Simultaneous Component Analysis.
Mitra V; Govorukhina N; Zwanenburg G; Hoefsloot H; Westra I; Smilde A; Reijmers T; van der Zee AG; Suits F; Bischoff R; Horvatovich P
Anal Chem; 2016 Apr; 88(8):4229-38. PubMed ID: 26959230
[TBL] [Abstract][Full Text] [Related]
30. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
Yoneyama T; Ohtsuki S; Honda K; Kobayashi M; Iwasaki M; Uchida Y; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Huang W; Yamada T; Tachikawa M; Terasaki T
PLoS One; 2016; 11(8):e0161009. PubMed ID: 27579675
[TBL] [Abstract][Full Text] [Related]
31. Quantitative analysis of single amino acid variant peptides associated with pancreatic cancer in serum by an isobaric labeling quantitative method.
Nie S; Yin H; Tan Z; Anderson MA; Ruffin MT; Simeone DM; Lubman DM
J Proteome Res; 2014 Dec; 13(12):6058-66. PubMed ID: 25393578
[TBL] [Abstract][Full Text] [Related]
32. Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach.
Park J; Lee E; Park KJ; Park HD; Kim JW; Woo HI; Lee KH; Lee KT; Lee JK; Park JO; Park YS; Heo JS; Choi SH; Choi DW; Jang KT; Lee SY
Oncotarget; 2017 Jun; 8(26):42761-42771. PubMed ID: 28514751
[TBL] [Abstract][Full Text] [Related]
33. A Cost-Effective High-Throughput Plasma and Serum Proteomics Workflow Enables Mapping of the Molecular Impact of Total Pancreatectomy with Islet Autotransplantation.
Bennike TB; Bellin MD; Xuan Y; Stensballe A; Møller FT; Beilman GJ; Levy O; Cruz-Monserrate Z; Andersen V; Steen J; Conwell DL; Steen H
J Proteome Res; 2018 May; 17(5):1983-1992. PubMed ID: 29641209
[TBL] [Abstract][Full Text] [Related]
34. Untargeted multi-omic analysis of colorectal cancer-specific exosomes reveals joint pathways of colorectal cancer in both clinical samples and cell culture.
Eylem CC; Yilmaz M; Derkus B; Nemutlu E; Camci CB; Yilmaz E; Turkoglu MA; Aytac B; Ozyurt N; Emregul E
Cancer Lett; 2020 Jan; 469():186-194. PubMed ID: 31669517
[TBL] [Abstract][Full Text] [Related]
35. A comparative proteomic study of plasma in feline pancreatitis and pancreatic carcinoma using 2-dimensional gel electrophoresis to identify diagnostic biomarkers: A pilot study.
Meachem MD; Snead ER; Kidney BA; Jackson ML; Dickinson R; Larson V; Simko E
Can J Vet Res; 2015 Jul; 79(3):184-9. PubMed ID: 26130850
[TBL] [Abstract][Full Text] [Related]
36. Pre- and Post-analytical Factors in Biomarker Discovery.
Klont F; Horvatovich P; Govorukhina N; Bischoff R
Methods Mol Biol; 2019; 1959():1-22. PubMed ID: 30852812
[TBL] [Abstract][Full Text] [Related]
37. Data independent acquisition of plasma biomarkers of response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma.
O'Rourke MB; Sahni S; Samra J; Mittal A; Molloy MP
J Proteomics; 2021 Jan; 231():103998. PubMed ID: 33027703
[TBL] [Abstract][Full Text] [Related]
38. Rapid sample preparation workflow based on enzymatic nanoreactors for potential serum biomarker discovery in pancreatic cancer.
Zhu C; Yang S; Li H; Wang Y; Xiong Y; Shen F; Zhang L; Yang P; Liu X
Talanta; 2022 Feb; 238(Pt 2):123018. PubMed ID: 34808569
[TBL] [Abstract][Full Text] [Related]
39. RNA-Binding Motif Protein 6 is a Candidate Serum Biomarker for Pancreatic Cancer.
Duan B; Hu X; Fan M; Xiong X; Han L; Wang Z; Tong D; Liu L; Wang X; Li W; Yang J; Huang C
Proteomics Clin Appl; 2019 Sep; 13(5):e1900048. PubMed ID: 31207145
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
